SUPERNUS PHARMACEUTICALS Business Summary

Supernus Pharmaceuticals, Inc. (SUPN) is a commercial-stage biopharmaceutical firm specializing in central nervous system (CNS) therapies, generating revenue primarily through net product sales in the Psychiatry and Neurology segments. The company’s 2026 strategy centers on its "four growth products": Qelbree (non-stimulant ADHD), GOCOVRI (Parkinson’s dyskinesia), ZURZUVAE (postpartum depression, integrated via the 2025 Sage Therapeutics acquisition), and the newly launched ONAPGO apomorphine pump. While legacy epilepsy assets Trokendi XR and Oxtellar XR remain cash-flow contributors, the portfolio is rapidly shifting toward these high-margin branded growth drivers to offset generic competition. Supernus competes against Takeda, Jazz Pharmaceuticals, and Neurocrine Biosciences, positioning itself as a specialty mid-cap leader that utilizes proprietary drug-delivery platforms to improve therapeutic profiles in niche CNS markets. The company is led by Founder, President, and CEO Jack A. Khattar, whose pedigree includes serving as CEO of Shire Laboratories and holding leadership roles at CIMA Labs and Merck. The executive team includes SVP and CFO Timothy C. Dec, a 35-year finance veteran, and Chief Technical Operations Officer Frank Mottola, who assumed his role in mid-2025 to scale global manufacturing and supply chain operations. Clinical and scientific direction is provided by Chief Scientific Officer Padmanabh P. Bhatt, Ph.D., and Chief Medical Officer Jonathan Rubin, MD. Supernus maintains a strong institutional shareholder base, led by BlackRock, Vanguard, and Millennium Management, with a board chaired by NEA co-founder Charles W. Newhall III.